Tyra Biosciences
TYRA
116 hedge funds and large institutions have $778M invested in Tyra Biosciences in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 40 increasing their positions, 38 reducing their positions, and 14 closing their positions.
32,900% more call options, than puts
Call options by funds: $330K | Put options by funds: $1K
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
44% more capital invested
Capital invested by funds: $542M → $778M (+$237M)
5% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 38
2.2% less ownership
Funds ownership: 106.59% → 104.39% (-2.2%)
4% less funds holding
Funds holding: 121 → 116 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
+$5.78M |
| 2 |
CC
Commodore Capital
New York
|
+$3.14M |
| 3 |
EP
Eversept Partners
New York
|
+$3.11M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3M |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$7.7M |
| 2 |
SCM
Sio Capital Management
New York
|
-$3.37M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$3.36M |
| 4 |
Millennium Management
New York
|
-$3M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2.72M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
US Bancorp
Minneapolis,
Minnesota
| – | -$72.4K | -7,561 | Closed |
|
|
PAS
127
Point72 Asia (Singapore)
Singapore
| – | -$33.4K | -3,490 | Closed |
|
|
PD
128
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$22.3K | -2,330 | Closed |
|
|
CIAM
129
Caitong International Asset Management
Hong Kong
| – | -$5.45K | -569 | Closed |
|
TYRA Hedge Fund Activity: Q3 2025 in Review
116 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q3 2025, worth a combined $778M — up 44% from $542M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TYRA and 9 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 40 added.
The largest buyer was Caligan Partners, adding an estimated $5.78M. The largest seller was OrbiMed, exiting entirely with an estimated $7.7M sold.
- 116 institutional investors held Tyra Biosciences (TYRA) as of Q3 2025, down from 121 in Q2 2025.
- Funds reported $778M of Tyra Biosciences stock for Q3 2025, up 44% quarter-over-quarter.
- 9 funds opened new Tyra Biosciences positions in Q3 2025 and 14 closed out, a net change of -5 holders.
- The largest Tyra Biosciences buyer in Q3 2025 was Caligan Partners, an estimated $5.78M added.
- The largest Tyra Biosciences seller in Q3 2025 was OrbiMed, an estimated $7.7M sold.
Based on aggregated 13F filings for Q3 2025.